Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Joseph, Gricar"'
Publikováno v:
Thoracic Cancer, Vol 13, Iss 9, Pp 1240-1257 (2022)
Abstract Background Esophageal cancer is a highly prevalent cancer associated with low survival, especially among those with advanced disease. Second‐line (2L) treatment patterns and related clinical outcomes of patients with advanced esophageal sq
Externí odkaz:
https://doaj.org/article/22e267d7dbc348b8959218323a02159f
Publikováno v:
Future Oncology. 18:927-936
Aim: To characterize real-world patterns of second-line treatment and outcomes in older patients with advanced/metastatic esophageal squamous cell carcinoma (ESCC). Patients and methods: Patients aged ≥66 years diagnosed with advanced/metastatic ES
Autor:
Yuichiro, Doki, Jaffer A, Ajani, Ken, Kato, Jianming, Xu, Lucjan, Wyrwicz, Satoru, Motoyama, Takashi, Ogata, Hisato, Kawakami, Chih-Hung, Hsu, Antoine, Adenis, Farid, El Hajbi, Maria, Di Bartolomeo, Maria I, Braghiroli, Eva, Holtved, Sandra A, Ostoich, Hye R, Kim, Masaki, Ueno, Wasat, Mansoor, Wen-Chi, Yang, Tianshu, Liu, John, Bridgewater, Tomoki, Makino, Ioannis, Xynos, Xuan, Liu, Ming, Lei, Kaoru, Kondo, Apurva, Patel, Joseph, Gricar, Ian, Chau, Yuko, Kitagawa, Rachna T, Shroff
Publikováno v:
Doki, Y, Ajani, J A, Kato, K, Xu, J, Wyrwicz, L, Motoyama, S, Ogata, T, Kawakami, H, Hsu, C H, Adenis, A, El Hajbi, F, Di Bartolomeo, M, Braghiroli, M I, Holtved, E, Ostoich, S A, Kim, H R, Ueno, M, Mansoor, W, Yang, W C, Liu, T, Bridgewater, J, Makino, T, Xynos, I, Liu, X, Lei, M, Kondo, K, Patel, A, Gricar, J, Chau, I, Kitagawa, Y & CheckMate 648 Trial Investigators 2022, ' Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma ', The New England Journal of Medicine, vol. 386, no. 5, pp. 449-462 . https://doi.org/10.1056/NEJMoa2111380
BACKGROUND: First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esoph
Autor:
John A. Bridgewater, Ian Chau, Joseph Gricar, Steven I. Blum, Fiona Taylor, Rachael Lawrance, Brad Padilla, Christine Yip, Lucjan Wyrwicz
Publikováno v:
Journal of Clinical Oncology. 40:262-262
262 Background: This analysis evaluated HRQoL as exploratory endpoints in CheckMate 648, a randomized, open-label, global Phase 3 study, evaluating treatment with N+I, N+CT and CT alone in inoperable advanced, recurrent, or metastatic ESCC. Methods:
Publikováno v:
Current Medical Research and Opinion. 26:2823-2832
To estimate the burden of illness (BOI) of hypertension in a cohort of women receiving menopausal hormone therapy (HT).Patients with at least one prescription for menopausal HT were selected from the PharMetrics database during the period July 1, 200
Autor:
Joseph J. Medicis, Emmanuel M. Mahlis, Nate J. Smith, Rachel Beckerman, Joseph Gricar, John C. Messina, Fulton F. Velez, Ramy A. Mahmoud
Publikováno v:
Journal of Allergy and Clinical Immunology. 141:AB165
Publikováno v:
Journal of Women's Health. 17:987-992
Contraceptive use in the United States is virtually universal among women of reproductive age. However, unplanned pregnancies continue to occur and can be largely attributed to the nonuse and misuse of contraception. Reducing unintended pregnancies c
Autor:
Samir H. Mody, Sanjay Merchant, Kristine Ogden, Steve Duff, Joseph Gricar, L Noe, Andrew Howe
Publikováno v:
Clinical therapeutics. 35(5)
Background: Opioids are commonly used to manage chronic pain. Although traditional -opioids are effective in reducing pain, they are often associated with opioid-induced side effects (OISEs) that can limit treatment effectiveness. Studies have shown
Publikováno v:
Applied health economics and health policy. 8(2)
Premenstrual syndrome (PMS) is reported to affect between 13% and 31% of women. Between 3% and 8% of women are reported to meet criteria for the more severe form of PMS, premenstrual dysphoric disorder (PMDD). Although PMDD has received increased att
Background The study was conducted to estimate the relative cost effectiveness of contraceptives in the United States from a payer's perspective. Methods A Markov model was constructed to simulate costs for 16 contraceptive methods and no method over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83328c8403223e4b030bb33807badb66
https://europepmc.org/articles/PMC3638200/
https://europepmc.org/articles/PMC3638200/